title: Current status of growth factors in the treatment of acute myeloid and lymphoblastic leukemia.
abstract: The safety of granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with acute leukemia has been well established in numerous clinical trials. The primary aim of these studies was to determine whether CSFs, when used as adjuncts to intensive chemotherapy, reduced the duration of neutropenia, prevented febrile neutropenia, infections, and hospitalization rates, and improved response and overall outcome in patients with acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL). Despite considerable efforts in divers clinical settings, the potential advantages of hematopoietic growth factors in the management of these leukemias remain inconclusive. In general, individual published trials have shown declines in the incidence and/or duration of neutropenia but have not consistently demonstrated a reduction in the overall frequency of infectious complications or the duration of hospitalization. Most protocols also have failed to show a benefit in terms of disease-free or overall survival. Nevertheless, improvements in "soft" clinical end points, such as incidence of severe infections, may be clinically important and contribute, even if only incrementally, to the patient's quality of life. Selection of those patients likely to benefit from growth factors in a specific clinical setting is a worthwhile endeavour.
authors.affiliation: Department of Hematology and Oncology, Johann Wolfgang Goethe University, Frankfurt/Main, Germany. ottmann@em.uni-frankfurt.de
authors.forename: Oliver G
authors.initials: OG
authors.lastname: Ottmann
authors.forename: Gesine
authors.initials: G
authors.lastname: Bug
authors.forename: Jürgen
authors.initials: J
authors.lastname: Krauter
mesh_terms: D000208:Acute Disease; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000097:blood / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D016207:Cytokines / Q000097:blood / Q000627:therapeutic use; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*; D006801:Humans; D007945:Leukemia, Lymphoid / Q000097:blood / Q000188:drug therapy*; D007951:Leukemia, Myeloid / Q000097:blood / Q000188:drug therapy*; D009503:Neutropenia / Q000097:blood / Q000188:drug therapy*
chemical_list: D016207:Cytokines; D016179:Granulocyte Colony-Stimulating Factor; D016178:Granulocyte-Macrophage Colony-Stimulating Factor